Neratinib induces estrogen receptor function and sensitizes HER2-mutant breast cancer to anti-endocrine therapy von Scaltriti, M, Carmona, F.J, Toska, E, Cocco, E, Hyman, D, Cutler, R, Avogadri-Connors, F, Wick, M.J, Papadopoulos, K.P, Lalani, A.S, Baselga, J

Volltext

227 REGN421/SAR153192, a fully human anti-Dll4 monoclonal antibody, blocks tumor growth by reducing tumor perfusion von Lalani, A.S, Kirshner, J.R, Abrahams, C, Eichten, A, Thurston, G

Volltext

1O Neratinib + capecitabine vs lapatinib + capecitabine in HER2+ metastatic breast cancer previously treated with ≥2 HER2-directed regimens: Exploratory biomarker analyses from pha... von Saura, C., Vivancos, A., Matito, J., Wildiers, H., Brufsky, A.M., Oliveira, M., Waters, S., Hurvitz, S.A., Moy, B., Kim, S-B., Gradishar, W.J., Queiroz, G.S., Cronemberger, E., Bebchuk, J., Keyvanjah, K., Lalani, A.S., Eli, L.D., Delaloge, S.

Volltext

HER-Seq: A blood-based genomic screening study to identify HER2 mutation-positive patients for enrollment into clinical trials with the pan-HER inhibitor neratinib von Tomasevic, Z., Smyth, L.M., Saura, C., Boni, V., Garcia-Sáenz, J.Á., Prat, A., Eli, L., Garza, S.J., Lalani, A.S., Crown, J.P.

Volltext

Neratinib in patients with HER2-mutant, metastatic cervical cancer: findings from the phase 2 SUMMIT ‘basket’ trial von D’Souza, A., Roman, L.D., Saura, C., Braña, I., Shapiro, G.I., Passalacqua, R., Piha-Paul, S., Cutler, R.E., Shahin, S., Eli, L.D., Xu, F., Dujka, M., Lalani, A.S., Bryce, R., Meric-Bernstam, F., Solit, D.B., Hyman, D.M.

Volltext

378 - Neratinib induces estrogen receptor function and sensitizes HER2-mutant breast cancer to anti-endocrine therapy von Scaltriti, M., Carmona, F.J., Toska, E., Cocco, E., Hyman, D., Cutler, R., Avogadri-Connors, F., Wick, M.J., Papadopoulos, K.P., Lalani, A.S., Baselga, J.

Volltext

1464P The impact of impaired renal function on the effectiveness of first-line immuno-oncology combination therapies in metastatic renal cell carcinoma (mRCC): Results from the int... von Navani, V., Ernst, M.S., Takemura, K., Pal, S.K., Powles, T.B., Donskov, F., Wells, J.C., Kollmannsberger, C.K., Beuselinck, B., Alva, A.S., Weickhardt, A.J., Lalani, A-K., Ernst, D.S., Agarwal, N., Choueiri, T.K., Heng, D.Y.C.

Volltext

Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma von Mason, Ross J, Wood, Lori, Kapoor, Anil, Basappa, Naveen, Bjarnason, George, Boorjian, Stephen A, Breau, Rodney H, Cagiannos, Ilias, Jewett, Michael A S, Karakiewicz, Pierre I, Kassouf, Wassim, Kollmannsberger, Christian, Lalani, Aly-Khan A, Lattouf, Jean-Baptiste, Lavallée, Luke T, Pautler, Stephen, Power, Nicholas, Richard, Patrick, So, Alan, Tanguay, Simon, Rendon, Ricardo A

Volltext

Practice patterns and perceptions of survivorship care in Canadian genitourinary oncology: A multidisciplinary perspective von Almatar, Ashraf, Richter, Suzanne, Lalani, Nafisha, Bender, Jackie L, Wiljer, David, Alkazaz, Nour, Legere, Laura, Maganti, Manjula, Sridhar, Srikala S, Catton, Pamela P, Jewett, Michael A S

Volltext

The impact of impaired renal function on the effectiveness of first-line immuno-oncology combination therapies in metastatic renal cell carcinoma (mRCC): Results from the internati... von Navani, V, Ernst, M.S, Takemura, K, Pal, S.K, Powles, T.B, Donskov, F, Wells, J.C, Kollmannsberger, C.K, Beuselinck, B, Alva, A.S, Weickhardt, A.J, Lalani, A.-K, Ernst, D.S, Agarwal, N, Choueiri, T.K, Heng, D.Y.C

Volltext